| Date | Title | Description | Source |
| 29.02.2024 | Often misdiagnosed, it's time to raise awareness of the rare... | (BPT) - What started as a dream trip to Hawaii became a medical turning point for Sally Cox. While s... | salamancap... |
| 04.10.2022 | A top Wall Street analyst names 3 tiny biotechs that look li... | The British pharma giant AstraZeneca has quietly been working on gene-editing research over the past... | businessin... |
| 08.04.2021 | FDA inspection of Emergent’s Baltimore site in 2020 rai... | The FDA on Thursday raised fresh quality concerns about Emergent BioSolutions’ manufactur... | endpts.com... |
| 04.04.2021 | Johnson & Johnson takes control of COVID vaccine output ... | Sign up for our daily briefingMake your busy days simpler with Axios AM/PM. Catch up on what's new a... | axios.com/... |
| 04.04.2021 | J&J Takes Over at Emergent Vaccine Plant With Aid From B... | (Bloomberg) --
Johnson & Johnson, with help from the Biden administration, is taking over a Balt... | bloombergq... |
| 06.01.2021 | AstraZeneca's Farxiga gets rough FDA review date for gro... | AstraZeneca’s Farxiga broke ground last year with an FDA nod for heart failure patients with or... | endpts.com... |
| 28.09.2016 | Hub appeal: AstraZeneca is marshaling 350-plus R&D t... | In biopharma, the big global hubs have become irresistible attractions as trophy location... | endpts.com... |
| 18.05.2015 | AstraZeneca invests in new biologics manufacturing facility ... | AstraZeneca invests in new biologics manufacturing facility in Södertälje, Sweden
18-05-2015
AstraZe... | cambridgen... |
| 22.03.2013 | Skepticism greets AstraZeneca in second round of changes ann... | Fabian Wenner, an analyst with Kepler Capital Markets SA in Zurich was not impressed by the changes.... | medcitynew... |
| 18.03.2013 | AstraZeneca shakes up R&D division with 1,600 staff cuts... | The pharmaceutical company said shifting its R&D sites to “bioscience hot spots” will make it ea... | medcitynew... |
| 05.09.2012 | FDA faces curse of double-edged sword over downside of accel... | Although European regulators asked for label changes, but said the drug’s benefits are still worth t... | medcitynew... |
| 05.07.2012 | Pitches unplugged: Startup developing iPad app to determine ... | But the company’s primary interest is advancing ownership of a diabetes model for which it plans to ... | medcitynew... |
| 13.04.2012 | AstraZeneca CEO faces familiar question on how to grow | Even Glass Lewis & Co., a proxy firm which seemed to support the management in its most recent r... | medcitynew... |
| 28.02.2012 | FDA’s new statin label warning about diabetes risk may have ... | In evaluating the new warning U.S. regulators are issuing on statin prescription labels, many physic... | medcitynew... |
| 19.01.2012 | FDA rejects diabetes drug from Bristol-Myers Squibb, AstraZe... | The FDA had delayed making a decision about the drug last October following an FDA advisory regulato... | medcitynew... |
| 18.12.2011 | 5 healthcare social media tips that break the mold for pharm... | Healthcare social media is becoming a necessity for pharmaceutical and medical device companies. Wit... | medcitynew... |
| 14.11.2011 | Endo Pharmaceuticals ends development of drug for growth hor... | Additionally, Endo discontinued development of the octreotide implant for the treatment of carcinoid... | medcitynew... |
| 02.11.2011 | Endo Pharmaceuticals gets green light for generic version of... | Endo, in Chadds Ford, Pennsylvania, saw a 439 percent surge in generic drug sales in the third quart... | medcitynew... |
| 27.10.2011 | Biotech forum offers stage for new and mature entrepreneurs | “It’s such an exciting opportunity to bring scientists together to rub elbows with business people. ... | medcitynew... |
| - | AstraZeneca CEO faces familiar question on how to grow | Amidst calls by shareholders for a management shakeup, AstraZeneca (NYSE: AZN) CEO David Brennen sou... | medcitynew... |
| - | 5 healthcare social media tips that break the mold for pharm... | Healthcare social media is becoming a necessity for pharmaceutical and medical device companies. Wit... | medcitynew... |
| - | Skepticism greets AstraZeneca in second round of changes ann... | In AstraZeneca’s (NYSE: AZN) statement outlining additional changes the drug maker will make to its ... | medcitynew... |
| - | FDA’s new statin label warning about diabetes risk may have ... | In evaluating the new warning U.S. regulators are issuing on statin prescription labels, many physic... | medcitynew... |
| - | Biotech forum offers stage for new and mature entrepreneurs | The Innovation Forum at the Biotech 2011 conference in Philadelphia this week sought to put scientis... | medcitynew... |
| - | Endo Pharmaceuticals gets green light for generic version of... | Endo Pharmaceuticals (NASDAQ: ENDP) has received approval from the Food and Drug Administration for ... | medcitynew... |
| - | AstraZeneca shakes up R&D division with 1,600 staff cuts... | AstraZeneca (NYSE:AZN) is revamping its research and development divisions to improve drug developme... | medcitynew... |
| - | FDA rejects diabetes drug from Bristol-Myers Squibb, AstraZe... | Bristol-Myers Squibb (NYSE:BMY) and AstraZeneca’s (NYSE:AZN) jointly developed treatment for type 2 ... | medcitynew... |
| - | Reframing the lung cancer narrative to increase survival rat... | This year in 2021, America will celebrate the 50th anniversary of the National Cancer Act, which est... | statnews.c... |
| - | Pitches unplugged: Startup developing iPad app to determine ... | A medication adherence tool, an innovative lighting solution embedded in a cane and a device to meas... | medcitynew... |
| - | FDA faces curse of double-edged sword over downside of accel... | The U.S. Food and Drug Administration frequently finds itself criticized for taking too long to appr... | medcitynew... |
| - | Endo Pharmaceuticals ends development of drug for growth hor... | Endo Pharmaceuticals (NASDAQ:ENDP) has ended its developments of an octreotide implant to treat a di... | medcitynew... |
| - | Covid-19 has exposed existing disparities among underserved ... | Underrepresented minority patient groups have historically faced diminished access to health care.
A... | statnews.c... |
| - | Inside the powerful political machines that COVID-19 vaccine... | A man walks in front of Pfizer headquarters on November 18, 2020 in New York City. The company has d... | businessin... |
| - | Europe stocks close slightly lower after strong first half; ... | This is CNBC’s live blog covering European markets. | cnbc.com/2... |
| - | Advancing our blueprint for the new era of cancer care | By Chatrick Paul, SVP, Head of US Oncology Business, AstraZeneca
While the global pandemic has disru... | statnews.c... |
| - | Following the science to improve patient outcomes in respira... | It is not widely known that there are several commonalities between respiratory and immunologic-driv... | statnews.c... |
| - | Survey of patient organizations finds cancer science communi... | The scientific understanding of the causes and mechanisms of cancers has advanced in recent years en... | statnews.c... |
| - | From the lab to the patient: Priti’s story | By Priti Patel, MD, Vice President, Clinical Development, Hematology, AstraZeneca
Approximately ever... | statnews.c... |
| - | CNBC Daily Open: Tesla roars in a quiet market | This report is from today’s CNBC Daily Open, our new, international markets newsletter. CNBC Daily O... | cnbc.com/2... |
| - | Stocks making the biggest moves in the premarket: Tesla, App... | Check out the companies making headlines in premarket trading.
Tesla — Tesla shares popped nearly 7%... | cnbc.com/2... |
| - | Stocks making the biggest moves midday: Tesla, Rivian, XPeng... | Check out the companies making headlines in midday trading.
Electric vehicles — Electric vehicle mak... | cnbc.com/2... |
| - | How a leading company in respiratory medicine is pushing the... | Each year, innovation continues to push the boundaries of science, resulting in research that delive... | statnews.c... |
